Drug Trial Radar · NCT02457598
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
Last checked: Nov 20, 2026Latest source record: Jun 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
203
Actual
Start
Jun 16, 2015
Primary completion
Sep 25, 2024
Study completion Sep 25, 2024
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- May 29, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of tirabrutinib (ONO/GS-4059) in combination with other targeted anti-cancer therapies and to evaluate the long-term safety of tirabrutinib as a monotherapy and in combination with other targeted anti-cancer therapies in adults with relapsed or refractory B-cell lymphoproliferative malignancies. This study consists of three parts: Dose Escalation, Dose Expansion, and Long-term Safety Monitoring. During the Dose Escalation phase, participants will be sequentially enrolled in a standard 3 + 3 dose escalation study design, to receive oral tirabrutinib combined with idelalisib entospletinib +/- obinutuzumab. The Dose Expansion Phase will enroll additional participants with a single B-cell lymphoproliferative malignancy disease type to further evaluate efficacy, safety, tolerability, PK, and pharmacodynamics. The Long-term Safety Monitoring phase will evaluate the long-term safety of tirabrutinib both as a monotherapy and in combination with other anti-cancer therapies. As of Amendment 9, all participants currently on the study who have no clinical evidence of disease progression will transition into long-term safety monitoring. Participants from the ongoing Study GS-US-401-1787 and participants who came off Study GS-US-401-1757 and Study GS-US-401-1787 but continued to receive treatment via named patient use (or individual expanded use) will be enrolled into the long-term safety monitoring group (Group VI). Participants enrolled in Group VI will continue the same treatment regimen in Study GS-US-401-1787 or named patient use (or individual expanded use). As of Protocol Amendment 8, the maximum treatment duration for any participant is an additional 6 years from the date of this amendment (ie. until November 2025). As of Amendment 9, entospletinib will be provided until 31 December 2020 to participants who are currently receiving entospletinib. Participants treated with entospletinib as part of a combination regimen with tirabrutinib will stop receiving entospletinib by 31 December 2020 but may continue to be treated with tirabrutinib monotherapy. Idelalisib will be provided as 50 mg tablets until 31 December 2020 and 100 mg tablets until study completion. Participants assigned to the 50 mg tablet will be given the option, at the investigator's discretion, to switch to 100 mg once daily idelalisib dose.
Conditions
- B-cell Malignancies
Interventions
TirabrutinibDrug
Capsules or tablets administered orally
IdelalisibDrug
Tablets administered orally twice daily
EntospletinibDrug
Tablets administered orally
ObinutuzumabDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
- Objective Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) at Week 12 in Participants With Non-Chronic Lymphocytic Leukemia (CLL) Type NHLTime frame: Week 12
- ORR: Percentage of Participants With CR or PR in Participants With CLL at Week 24Time frame: Week 24
- Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Time frame: First dose up to last dose date (up to 441 weeks) plus 30 days
Locations
15 sites in 3 countries. Site status is shown where the registry gives one.
Georgetown University Medical Center
Washington D.C., District of Columbia
Indiana University Health Goshen Center for Cancer Care
Goshen, Indiana
Oregon Health and Science University
Portland, Oregon
CHRU de Lille, Hopital Claude Huriez
Lille, France
Hopital Saint Eloi
Montpellier, France
Chu Haut Leveque
Pessac, France
Centre Hospitalier de Lyon Sud
Pierre-Bénite, France
Institut Universitaire du Cancer-Oncopole I.U.C.T-O
Toulouse, France
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
Cardiff and Vale Health Board, Clinical Research Facility
Cardiff, United Kingdom
Leeds Teaching Hosptials NHS Trust, Dept of Haematology
Leeds, United Kingdom
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Plymouth Hospitals NHS Trust
Plymouth, United Kingdom
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.